Skip to contentHome page Seeking Alpha - Power to InvestorsTranscriptsJapanJan. 13, 2026 6:56 PM ETNxera Pharma Co., Ltd. (SOLTF) StockSA Transcripts157.66K FollowersCommentsNxera Pharma Co., Ltd. (SOLTF) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 4:30 PM ESTCompany ParticipantsChris Cargill - Representative Executive Officer, President, CEO & DirectorPatrik FoerchConference Call ParticipantsSeiji Wakao - JPMorgan Chase & Co, Research DivisionPresentationSeiji WakaoJPMorgan Chase & Co, Research DivisionGood afternoon, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan Pharma Analyst at JPMorgan. And it's my pleasure to introduce Chris Cargill, President and CEO of Nxera Pharma, and welcome him to the conference. Chris, please go ahead.Chris CargillRepresentative Executive Officer, President, CEO & DirectorExcellent. Well, good afternoon. It's great to be back at the JPMorgan Healthcare Conference. Thank you to our bankers at JPMorgan, and thank you all for being here. If you're new to Nxera Pharma, we are not a traditional or average Japanese pharma company. From our research labs in Cambridge, we pioneered structure-based drug discovery against GPCRs with the NxWave platform. And today, we leverage our proprietary data assets, coupled with advances in structural biology and AI. And the results, we've delivered 30 drug candidates over the past 12 years.Now in Japan, where we are headquartered, we've built a lean development and commercial business modeled on the U.S. go-to-market model, where our bilingual teams guide approval and launch to deliver specialty and rare disease-focused medicines to patients with unmet needs in Japan.I'm pleased to say that both sides of the business are advancing to plan. The next wave drug discovery platforms productivity is unprecedented. We've now got 15 clinical programs that are being advanced by our partners across multiple therapeutic areas.On the commercial side in Japan, we've got 2 marketed medicines, PIVLAZ and QUVIVIQ. They continue to grow and make a real difference for patients. And just last week, we'reRead more current SOLTF analysis and newsView all earnings call transcriptsCommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.